Back to top

BMO Capital Sticks to Its Hold Rating for Biogen (BIIB)

BMO Capital analyst Evan Seigerman maintained a Hold rating on Biogen today and set a price target of $196.00. Seigerman covers the Healthcare sect...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Biogen Inc. (BIIB)